{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:10:06Z","timestamp":1793239806305,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","award":["MR\/T04201X\/1"],"award-info":[{"award-number":["MR\/T04201X\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bbadis.2022.166358","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:19:25Z","timestamp":1644373165000},"page":"166358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lessons from microRNA biology: Top key cellular drivers of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1016","volume":"1868","author":[{"given":"Maria","family":"Fragiadaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2022.166358_bb0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/482461a","article-title":"Turing centenary: life's code script","volume":"482","author":"Brenner","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166358_bb0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7861\/clinmedicine.9-3-278","article-title":"Autosomal dominant polycystic kidney disease","volume":"9","author":"Chow","year":"2009","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.bbadis.2022.166358_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bbadis.2022.166358_bb0020","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21238936","article-title":"The controversial role of fibrosis in autosomal dominant polycystic kidney disease","volume":"21","author":"Fragiadaki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2022.166358_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbadis.2022.166358_bb0035","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1065062","article-title":"An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans","volume":"294","author":"Lau","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2022.166358_bb0040","first-page":"3094","article-title":"MicroRNA-221: biogenesis, function and signatures in human cancers","volume":"22","author":"Abak","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2022.166358_bb0045","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0050","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2022.166358_bb0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.bbadis.2022.166358_bb0065","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5603\/PJNNS.a2021.0026","article-title":"miRNA-16 as a predictive factor for intracranial aneurysms in autosomal dominant polycystic kidney disease","volume":"55","author":"Kulesza","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0070","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.kint.2020.02.008","article-title":"Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease","volume":"98","author":"Magayr","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2022.166358_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133785","article-title":"Interstitial microRNA miR-214 attenuates inflammation and polycystic kidney disease progression","volume":"5","author":"Lakhia","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbadis.2022.166358_bb0080","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41598-019-38566-y","article-title":"Anti-microRNA screen uncovers miR-17 family within miR-17~92 cluster as the primary driver of kidney cyst growth","volume":"9","author":"Yheskel","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2022.166358_bb0085","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1096\/fj.201800563RR","article-title":"Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease","volume":"33","author":"Kim","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bbadis.2022.166358_bb0090","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1002\/jcp.26473","article-title":"MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR\/MDM2 pathway in ADPKD cells","volume":"233","author":"de Stephanis","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0095","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1096\/fj.201700923R","article-title":"Regulation of KLF12 by microRNA-20b and microRNA-106a in cystogenesis","volume":"32","author":"Shin","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bbadis.2022.166358_bb0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12882-017-0600-z","article-title":"Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function","volume":"18","author":"Kocyigit","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0105","doi-asserted-by":"crossref","first-page":"F577","DOI":"10.1152\/ajprenal.00607.2016","article-title":"Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression","volume":"312","author":"Streets","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0110","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1681\/ASN.2015060634","article-title":"MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease","volume":"27","author":"Lakhia","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.12659\/MSM.892141","article-title":"Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C","volume":"21","author":"Sun","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bbadis.2022.166358_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1752-0509-5-56","article-title":"Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease","volume":"5","author":"Pandey","year":"2011","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0125","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1073\/pnas.1301693110","article-title":"miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease","volume":"110","author":"Patel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0130","doi-asserted-by":"crossref","first-page":"15060","DOI":"10.1038\/ncomms15060","article-title":"Cell-size dependent progression of the cell cycle creates homeostasis and flexibility of plant cell size","volume":"8","author":"A","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2022.166358_bb0135","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbadis.2022.166358_bb0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","article-title":"G1 phase progression: cycling on cue","volume":"79","author":"Sherr","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0145","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMra1010172","article-title":"Ciliopathies","volume":"364","author":"Hildebrandt","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0150","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","article-title":"Regulation of the G2\/M transition by p53","volume":"20","author":"Taylor","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166358_bb0155","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1681\/ASN.2012030321","article-title":"MicroRNAs regulate renal tubule maturation through modulation of Pkd1","volume":"23","author":"Patel","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-013-1000-x","article-title":"Conditional loss of kidney microRNAs results in congenital anomalies of the kidney and urinary tract (CAKUT)","volume":"91","author":"Bartram","year":"2013","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbadis.2022.166358_bb0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0005-2760(98)00139-8","article-title":"Structure and function of phosphoinositide 3-kinases","volume":"1436","author":"Wymann","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2022.166358_bb0170","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1158\/0008-5472.CAN-09-1077","article-title":"Genetic alterations in the phosphoinositide 3-kinase\/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2022.166358_bb0185","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/onc.2011.324","article-title":"PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma","volume":"31","author":"Molina","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166358_bb0190","doi-asserted-by":"crossref","first-page":"32081","DOI":"10.1074\/jbc.M502876200","article-title":"Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity","volume":"280","author":"Hahn-Windgassen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2022.166358_bb0195","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0200","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0205","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0210","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119396","article-title":"MicroRNA-21 regulates PI3K\/Akt\/mTOR signaling by targeting TGF beta I during muscle development in pigs","volume":"10","author":"Bai","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.bbadis.2022.166358_bb0225","article-title":"Supportive interaction of PI3K-akt-mTOR and STAT3-miR21-PTEN controls IgE induced airway remodeling","volume":"52","author":"Fang","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bbadis.2022.166358_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijo.2012.1707","article-title":"MiR-21 regulates biological behavior through the PTEN\/PI-3 K\/Akt signaling pathway in human colorectal cancer cells","volume":"42","author":"Xiong","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0235","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1681\/ASN.2015060634","article-title":"MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease","volume":"27","author":"Lakhia","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MNH.0000000000000333","article-title":"Therapeutic microRNAs in polycystic kidney disease","volume":"26","author":"Yheskel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bbadis.2022.166358_bb0245","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2022.166358_bb0250","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0255","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166358_bb0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2022.166358_bb0265","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1073\/pnas.94.14.7239","article-title":"Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression","volume":"94","author":"Udy","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0270","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa022926","article-title":"Growth hormone insensitivity associated with a STAT5b mutation","volume":"349","author":"Kofoed","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0275","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/nm1659","article-title":"STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression","volume":"13","author":"Zhang","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2022.166358_bb0280","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/1878-0261.12846","article-title":"Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma","volume":"15","author":"Jiang","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0285","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428194.2018.1543875","article-title":"MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5","volume":"60","author":"Jiang","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbadis.2022.166358_bb0290","first-page":"1180","article-title":"MiRNA-1469 promotes lung cancer cells apoptosis through targeting STAT5a","volume":"5","author":"Xu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0295","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","article-title":"Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways","volume":"20","author":"Takakura","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2022.166358_bb0300","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0305","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00109-019-01852-3","article-title":"Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury\/repair response and PKD progression","volume":"97","author":"Formica","year":"2019","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbadis.2022.166358_bb0310","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1073\/pnas.1111966108","article-title":"Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease","volume":"108","author":"Olsan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0315","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2022.166358_bb0320","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2019090959","article-title":"Tubular STAT3 limits renal inflammation in autosomal dominant polycystic kidney disease","volume":"31","author":"Viau","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0092-8674(02)00716-X","article-title":"PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2","volume":"109","author":"Bhunia","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0330","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.kint.2016.10.039","article-title":"STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease","volume":"91","author":"Fragiadaki","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2022.166358_bb0335","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.onc.1205148","article-title":"Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase","volume":"21","author":"Morcinek","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166358_bb0340","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/sj.onc.1203526","article-title":"The role of STAT proteins in growth hormone signaling","volume":"19","author":"Herrington","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166358_bb0345","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1038\/s41598-019-41106-3","article-title":"Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis","volume":"9","author":"Patera","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2022.166358_bb0350","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.3892\/mmr.2015.3298","article-title":"MicroRNA-204 targets signal transducer and activator of transcription 5 expression and inhibits proliferation of B-cell lymphoma cells","volume":"11","author":"Wu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbadis.2022.166358_bb0355","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/dvg.22023","article-title":"The miR-17\/92 cluster is targeted by STAT5 but dispensable for mammary development","volume":"50","author":"Feuermann","year":"2012","journal-title":"Genesis"},{"key":"10.1016\/j.bbadis.2022.166358_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085123","article-title":"MiR-21 is under control of STAT5 but is dispensable for mammary development and lactation","volume":"9","author":"Feuermann","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2022.166358_bb0365","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA damage as a source of genomic instability in cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0370","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cell.2015.08.034","article-title":"Deciphering the DNA damage response","volume":"162","author":"Haber","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0375","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62852","article-title":"DNA damage-how and why we age?","volume":"10","author":"Yousefzadeh","year":"2021","journal-title":"elife"},{"key":"10.1016\/j.bbadis.2022.166358_bb0380","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0385","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cell.2005.09.038","article-title":"MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks","volume":"123","author":"Stucki","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0390","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbadis.2022.166358_bb0395","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2022.166358_bb0400","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1038\/s41467-019-13610-7","article-title":"A model of DNA damage response activation at stalled replication forks by SPRTN","volume":"10","author":"Bruhn","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2022.166358_bb0405","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1016\/j.cub.2016.11.025","article-title":"DNA replication checkpoint: new ATR activator identified","volume":"27","author":"Zou","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0410","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166358_bb0415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2022.166358_bb0420","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2010.10.020","article-title":"p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome","volume":"47","author":"Ryan","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2022.166358_bb0425","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2022.166358_bb0430","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/MCB.01446-14","article-title":"MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1","volume":"35","author":"Bouamar","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0435","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcb.25609","article-title":"MicroRNA control of p53","volume":"118","author":"Liu","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbadis.2022.166358_bb0440","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jmcb\/mjq040","article-title":"Tumor suppressor p53 meets microRNAs","volume":"3","author":"Feng","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0445","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1158\/0008-5472.CAN-08-1569","article-title":"p53-responsive micrornas 192 and 215 are capable of inducing cell cycle arrest","volume":"68","author":"Braun","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0450","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0188-0128(98)00011-6","article-title":"Monitoring of molecular and cytogenetic damage in lymphocytes from three persons with polycystic kidney disease","volume":"30","author":"Cebulska-Wasilewska","year":"1999","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.bbadis.2022.166358_bb0455","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ajpath.2021.01.011","article-title":"Up-regulation of DNA damage response signaling in autosomal dominant polycystic kidney disease","volume":"191","author":"Zhang","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0460","article-title":"Effect of reducing ataxia-telangiectasia mutated (ATM) in experimental autosomal dominant polycystic kidney disease","volume":"10","author":"Zhang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2022.166358_bb0465","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.molcel.2013.08.006","article-title":"NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies","volume":"51","author":"Choi","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbadis.2022.166358_bb0470","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1172\/JCI22850","article-title":"Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation","volume":"115","author":"Nishio","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2022.166358_bb0475","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","article-title":"Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease","volume":"123","author":"Zhou","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2022.166358_bb0480","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.ejhg.5201136","article-title":"Depletion of PKD1 by an antisense oligodeoxynucleotide induces premature G1\/S-phase transition","volume":"12","author":"Kim","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2022.166358_bb0485","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CS20090557","article-title":"Role of nuclear factor kappaB in cardiovascular health and disease","volume":"118","author":"Van der Heiden","year":"2010","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.bbadis.2022.166358_bb0490","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jmb.2008.05.048","article-title":"Transfer of flexibility between ankyrin repeats in I kappa B alpha upon formation of the NF-kappa B complex","volume":"380","author":"Sue","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0495","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2215\/CJN.04140510","article-title":"Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease","volume":"6","author":"Menon","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0500","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5527\/wjn.v5.i4.339","article-title":"Constitutive renal Rel\/nuclear factor-kappaB expression in Lewis polycystic kidney disease rats","volume":"5","author":"Ta","year":"2016","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.bbadis.2022.166358_bb0505","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ki.1991.87","article-title":"Cytokines in fluids from polycystic kidneys","volume":"39","author":"Gardner","year":"1991","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2022.166358_bb0510","article-title":"TNFalpha signaling regulates cystic epithelial cell proliferation through Akt\/mTOR and ERK\/MAPK\/Cdk2 mediated Id2 signaling","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2022.166358_bb0515","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfw058","article-title":"Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor kappaB-induced inflammation","volume":"31","author":"Wu","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bbadis.2022.166358_bb0520","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","article-title":"Inhibitors of NF-kappaB signaling: 785 and counting","volume":"25","author":"Gilmore","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2022.166358_bb0525","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/813804","article-title":"Amelioration of severe TNBS induced colitis by novel AP-1 and NF- kappa B inhibitors in rats","volume":"2014","author":"El-Salhy","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bbadis.2022.166358_bb0530","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:08:16Z","timestamp":1760418496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443922000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0925443922000217"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166358","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons from microRNA biology: Top key cellular drivers of Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166358"}}